Additionally, a recent study has suggested that RGS16 can be used as a diagnostic biomarker for immune subtypes of ovarian cancer and as a biomarker to predict the clinical stage of the disease (Hu et al., 2021). This evidence concerns the gene RGS16 and ovarian cancer.